INACTIVATION OF HIV

HIV 灭活

• 批准号: 3358833
• 负责人: Bernard Horowitz
• 金额: $ 37.3万
• 依托单位: NEW YORK BLOOD CENTER
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-07-01 至 1992-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3358833
• 关键词: Pan; alkylating agents; antiviral agents; blood banks; blood preservation; blood proteins; blood transfusion; cell free system; clotting factor; cryopreservation; detergents; erythrocytes; gamma radiation; hepatitis B virus group; hepatitis C virus; human immunodeficiency virus 1; human subject; microwave radiation; platelets; radiosensitizer; tissue /cell culture; ultraviolet radiation

The transmission of pathogenic agents by transfusion of cellular and protein products derived from blood is an ongoing and serious problem. The proposed studies are designed to evaluate both physical and chemical approaches for the inactivation of viruses in these products. Process methods will be selected initially on the basis of sterilization efficacy against easily quantifiable viruses, and of recovery of intact and functioning red cells, platelets, and plasma coagulation factors. After promising approaches have been identified, their efficiency in inactivating HIV and type B and non-A, non-B hepatitis viruses will be evaluated in tissue culture and in chimpanzees, respectively. Finally, demonstration lots of virus sterilized fresh frozen plasma, cryoprecipitate, and units of red blood cell and platelet concentrates will be prepared and evaluated clinically. The New York Blood Center is especially well suited to accomplish these goals because of its extensive research with blood borne viruses, its experience in developing and evaluating methods of virus inactivation applicable to purified protein derivatives, and because of the availability of our primate facility in Liberia. This project will further benefit from our supply of resource material; our laboratory, pilot plant, and components facilities; and our experience in handling and analyzing plasma proteins and blood components and in preparing experimental and licensed biologics for therapeutic use in humans.

通过细胞输注传播病原体 从血液中提取的蛋白质产品是一个持续且严重的问题 问题。 拟议的研究旨在评估 灭活病毒的物理和化学方法 在这些产品中。 处理方法将首先选择 灭菌功效的基础易于量化 病毒，以及完整和功能性红细胞的恢复， 血小板和血浆凝固因子。 承诺之后 已经确定了方法，它们在灭活方面的效率 HIV 和 B 型以及非甲、非乙型肝炎病毒将 分别在组织培养和黑猩猩中进行评估。 最后展示大量病毒灭菌的新鲜冰冻血浆， 冷沉淀、红细胞和血小板单位 将制备浓缩物并进行临床评估。 纽约血液中心特别适合 由于其广泛的研究，实现了这些目标 血源性病毒的开发和评估经验 适用于纯化蛋白的病毒灭活方法 衍生物，并且由于我们灵长类动物设施的可用性 在利比里亚。 该项目将进一步受益于我们的供应 资源材料；我们的实验室、中试工厂和组件 设施;以及我们在处理和分析血浆方面的经验 蛋白质和血液成分以及制备实验和 用于人类治疗用途的许可生物制剂。